Aprea Therapeutics (APRE) Earnings Date, Estimates & Call Transcripts → A new way to collect income from stocks (From DTI) (Ad) Free APRE Stock Alerts $5.37 +0.25 (+4.88%) (As of 09:55 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 20EstimatedActual EPS (Mar. 26) -$0.92 Missed By -$0.36 Consensus EPS (Mar. 26) -$0.56 Get Aprea Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for APRE and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueAPRE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.APRE Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. Aprea Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.80)($0.75)($0.78)Q2 20242($0.81)($0.80)($0.81)Q3 20242($0.87)($0.79)($0.83)Q4 20242($0.93)($0.14)($0.54)FY 20248($3.41)($2.48)($2.95)Q1 20251($1.00)($1.00)($1.00)Q2 20251($0.26)($0.26)($0.26)Q3 20251($0.28)($0.28)($0.28)Q4 20251($0.31)($0.31)($0.31)FY 20254($1.85)($1.85)($1.85)APRE Earnings Date and InformationAprea Therapeutics last announced its earnings data on March 26th, 2024. The reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.36. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.33 million. Aprea Therapeutics has generated ($3.99) earnings per share over the last year (($3.99) diluted earnings per share). Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.38) to ($0.96) per share. Aprea Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.Read More Aprea Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/20/2024Estimated)------- 3/26/2024Q4 2023($0.56)($0.92)($0.36)($0.92)$0.33 million$0.01 million11/9/2023Q3 2023($1.08)($0.86)+$0.22($0.86)$0.25 million$0.32 million8/10/2023Q2 2023($1.43)($0.87)+$0.56($0.87)-$0.25 million5/15/2023Q1 2023($1.51)($1.34)+$0.17($1.34)--3/30/2023Q4 2022($2.60)($0.92)+$1.68($0.92)--11/9/2022Q3 2022($5.60)($2.40)+$3.20($0.12)-- Get the Latest News and Ratings for APRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q2 2022($7.60)($19.80)($12.20)$2.36--5/16/2022Q1 2022($7.60)($7.20)+$0.40($0.36)--3/15/2022Q4 2021($8.80)($7.20)+$1.60($0.36)--11/8/2021Q3 2021($9.00)($9.00)-($0.45)--8/12/2021Q2 2021($9.40)($9.60)($0.20)($0.48)--5/6/2021Q1 2021($9.80)($9.20)+$0.60($0.46)-- Aprea Therapeutics Earnings - Frequently Asked Questions When is Aprea Therapeutics's earnings date? Aprea Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on APRE's earnings history. Did Aprea Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aprea Therapeutics (NASDAQ:APRE) missed the analysts' consensus estimate of ($0.56) by $0.36 with a reported earnings per share (EPS) of ($0.92). Learn more on analysts' earnings estimate vs. APRE's actual earnings. How much revenue does Aprea Therapeutics generate each year? Aprea Therapeutics (NASDAQ:APRE) has a recorded annual revenue of $580,000.00. How much profit does Aprea Therapeutics generate each year? Aprea Therapeutics (NASDAQ:APRE) has a recorded net income of -$14.29 million. APRE has generated -$3.99 earnings per share over the last four quarters. What is Aprea Therapeutics's EPS forecast for next year? Aprea Therapeutics's earnings are expected to grow from ($2.38) per share to ($0.96) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Theratechnologies Earnings CASI Pharmaceuticals Earnings Lexaria Bioscience Earnings JanOne Earnings Spruce Biosciences Earnings Viracta Therapeutics Earnings Fortress Biotech Earnings ImmunoPrecise Antibodies Earnings VYNE Therapeutics Earnings Enlivex Therapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:APRE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.